drugset / Trial / NCT02868801

Efficacy and Safety of Pregabalin Sustained Release Tablet for Postherpetic Neuralgia

NCT02868801

Phase 3 Unknown 280 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the Efficacy and safety of pregabalin sustained release tablet versus placebo for postherpetic neuralgia.

Timeline

Start
2015-03
Primary completion
2017-06
Completion
2017-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 330 mg Oral
Subject Pregabalin Small molecule 660 mg Oral